Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It also mentioned them wasting billions on failed contracts, so they would most certainly want to take there time ?
I said on here last month there was a piece in the times regarding glaxco looking at small pharmas for there cancer portfolio . ? We willl see
If you listen from 15:34 this is the part I meant, he mentions another company several times that he cannot disclose, and couldn't disclose in the RNS at the point where legally they had to release the fact global didn't take the option. Maybe I'm reading between the lines but it all sounds like he's frustrated he can't reveal the fuller picture here yet.
They did say they are always looking at financing options so at least there is admission that Mint is not ideal! Although, when asked something along the lines of whether Mint were trying to damage the company, he said he "didn't think so". I would have liked a more confident response on that.
I would have to listen to that part again. I don't recall thinking it had anything to do with a other company, but more that taking the option wasn't a viable business decision for Global co, probably in terms of their strategic guidelines and targets, rather than because the actual product isn't feasible.
Any thoughts on the part where he says (ref the option) "it was purely a business decision"... and he knows what stands behind the decision but he cannot talk about it "without disclosing their name" and he is not yet allowed to disclose the name of that company. Which company? Is it potentially as simple as someone came in with a better offer?
It's possible ferg.
Ssccss I didn't hear it quite like that, if it was as simple as them not taking it meant HEMO have full control, they could easily have said that, but he says it's just the first part of the story and that it's challenging to give the full picture in that RSN but they had to legally announce the fact they didn't take the option at that time. To me it sounds like something bigger is already lined or lining up, they just can't obviously announce what until all the i's are dotted etc.
I have to say the stuff Vlad said about competitors pipping them to the post was something I hadn't considered and does place an additional time pressure on product development. What Hemo is trying to achieve is certainly not easy but hopefully, worthwhile in the longer term.
I'm pretty sure he said if Global co has taken the option and then decided not to further the research on CDX, then it would be finished. Hemo couldn't continue it. That's what I got from what he said. So Vlad sees it as a positive because he obviously believes in the product whereas Global co have different business drivers which may clash with Hemo's objectives. He also said there wouldn't have been much money in them taking the option as far as I can tell. So the only benefit Global co has is assisting with the tech and trials, which of course is very needed. They will however, not be bearing much risk. Hemo is willing to do that though.
Vlad said Global co not taking the option was not a bad thing because it means Hemo retains some control over the product, whereas all control was gone under the option. So in the long run, it will work out better for Hemo if the product is proven to be successful.
I think 13:35 was the key part of the interview because he wanted to stress global co not taking the option was not actually a bad thing, but couldn't tell us why yet. Maybe it's all just talk but well it got me xD
I've averaged one of my holdings here down to 5.9p from 10p, convinced after that interview Vlad knows something exciting is on the horizon he wants to tell us but can't yet (legally). Hopefully I'm not throwing good money after bad, has to be a massive up side from these rates though, happy to wait it out.
Well:I did average down @ 4,25
That would be nice for you Pumpky lol
Sure Mint will convert at every opportunity;Hopefully a nice Covid update and the SP flies to 7 pence;allowing my 5 week day trade into profit
I don't think anyone is questioning Hemo's scientific expertise and ability to do clinical trials with help from larger pharma. I am also much happier with the changes to the communication. The uncertainty for me is primarily regarding short to medium term financing and specifically the future unpredictable (or predictable, as the case may be) behaviour of Mint.
Hi All,
I recall during the fallout last week there was a post by MyLucy in which a revisit of their research and why he/she originally invested. You have only to read the RNS re HEMO CAR-T to be confident that Hemogenyx are involving the necessary expertise in "Quality Systems" run by Randall Tlachac to take this product forward. Mr Sandler is not on his own here and QS have a great pedigree. I am a holder. GLA
Been a hell of a lot of buying and selling in the last week - who knows where we are at with teh supply and demand.
The timing of the recovery will almost certainly take us by surprise....
A director buy would go a long way to repairing the SP. Dig deep Vlad.
Or a month of 5% increases. Long road to recovery but end game is still the same - products to trials and market!
Dont need the cash right now so another year won’t hurt! By then we’ll be multiples of here without doubt!
If Mint are the ones selling:the sells will not dry up for a long while Imho
thanks for your feedback ... i will top up a little to drag my average down a little. wish i had more money but i feel a little more positive now ... just have to wait and hope the next RNS is a big one
MrIndia - market and company sentiment, bit of positive PR, and clearly when a seller is finished up their is less supply
@Digitt - my bad. I was thinking the conversions flowed money into Hemo. They dont, they reduce the debt
No TR1 again